Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Helman

Showing results (21-30 of 211) with videos related to

Pageof 22
Sort By:
Current Opinion in Oncology|July 1, 1997
Cytogenetics and experimental modelsJ A Toretsky, L J Helman
Pediatric Clinics of North America|April 1, 1991
New insights into the causes of cancerL J Helman, C J Thiele
Journal of Pediatric Hematology/Oncology|July 24, 2001
High-dose chemotherapy for rhabdomyosarcoma: where do we go from hereC L Mackall, L J Helman
Hematology/Oncology Clinics of North America|April 24, 2012
Targeting the insulin growth factor receptor 1Fernanda I Arnaldez, Lee J Helman
Surgery, Gynecology & Obstetrics|March 19, 2010
Sodium pentothal anesthesia for selected vaginal obstetricsA L DIPPEL, R J HELMAN
The New England Journal of Medicine|November 24, 2021
New Horizons in the Treatment of OsteosarcomaPaul S Meltzer, Lee J Helman
The Journal of Endocrinology|June 1, 1996
Involvement of IGF-II in human cancerJ A Toretsky, L J Helman
Cancer Research|September 15, 1991
All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell linesG D Crouch, L J Helman
Cancer Treatment and Research|March 10, 2010
Strategies to explore new approaches in the investigation and treatment of osteosarcomaSu Young Kim, Lee J Helman
Cancer Discovery|May 16, 2012
Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenomePaul S Meltzer, Lee J Helman
Pageof 22

Showing results (21-30 of 211) with videos related to

Sort By:
Pageof 22
Current Opinion in Oncology|July 1, 1997
Cytogenetics and experimental modelsJ A Toretsky, L J Helman
Pediatric Clinics of North America|April 1, 1991
New insights into the causes of cancerL J Helman, C J Thiele
Journal of Pediatric Hematology/Oncology|July 24, 2001
High-dose chemotherapy for rhabdomyosarcoma: where do we go from hereC L Mackall, L J Helman
Hematology/Oncology Clinics of North America|April 24, 2012
Targeting the insulin growth factor receptor 1Fernanda I Arnaldez, Lee J Helman
Surgery, Gynecology & Obstetrics|March 19, 2010
Sodium pentothal anesthesia for selected vaginal obstetricsA L DIPPEL, R J HELMAN
The New England Journal of Medicine|November 24, 2021
New Horizons in the Treatment of OsteosarcomaPaul S Meltzer, Lee J Helman
The Journal of Endocrinology|June 1, 1996
Involvement of IGF-II in human cancerJ A Toretsky, L J Helman
Cancer Research|September 15, 1991
All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell linesG D Crouch, L J Helman
Cancer Treatment and Research|March 10, 2010
Strategies to explore new approaches in the investigation and treatment of osteosarcomaSu Young Kim, Lee J Helman
Cancer Discovery|May 16, 2012
Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenomePaul S Meltzer, Lee J Helman
Pageof 22